ZEPOSIA Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving ZEPOSIA Growth

1. Strong Commercial Growth and Expanding Revenue Base

Bristol Myers Squibb reported worldwide ZEPOSIA sales of approximately $566 million in 2024, representing about 30% year-over-year growth versus 2023 sales of $434 million. U.S. sales reached $403 million, while international revenue grew to $163 million, reflecting improving uptake across both MS and UC indications.

2. Dual Approved Indications Expand Addressable Patient Pool

ZEPOSIA is approved for:

• Relapsing forms of multiple sclerosis (RMS)
• Moderately-to-severely active ulcerative colitis (UC)

Having approvals in both neurology and gastroenterology significantly broadens prescribing opportunities. The FDA first approved ZEPOSIA for MS in 2020 and later approved it for UC in 2021.

3. Convenient Once-Daily Oral Administration

ZEPOSIA's once-daily oral dosing offers a major competitive advantage over injectable biologics and infusion therapies commonly used in MS and UC. This convenience supports patient adherence and physician preference, particularly among patients seeking to avoid infusion centers or injectable therapies.

4. Differentiated, Selective S1P Mechanism Supports Safety Positioning

ZEPOSIA selectively targets S1P receptors 1 and 5 with limited activity on receptors associated with broader cardiovascular adverse effects. Bristol Myers Squibb positions the drug as a highly selective S1P modulator, potentially improving tolerability compared with earlier-generation S1P therapies.

5. Growing Ulcerative Colitis Market and Demand for Advanced Oral Therapies

The UC market is rapidly shifting toward targeted oral therapies that can compete with biologics and JAK inhibitors. In the pivotal Phase III TRUE NORTH study, ZEPOSIA demonstrated efficacy in both induction and maintenance of remission in moderate-to-severe UC patients, including biologic-experienced patients. This has supported increasing gastroenterologist adoption.

ZEPOSIA Recent Developments

• In September 2024, Bristol Myers Squibb announced new data from the Phase III DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients treated with ZEPOSIA (ozanimod) for relapsing forms of multiple sclerosis. These findings showed that patients receiving continuous Zepoisia treatment for up to five years experienced low and stable rates of whole brain volume (WBV) loss through Month 60.

"ZEPOSIA Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of ZEPOSIA for approved indication like Multiple sclerosis and Ulcerative colitis; as well as potential indication like Crohn's disease in the 7MM. A detailed picture of ZEPOSIA's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the ZEPOSIA for approved and potential indications. The ZEPOSIA market report provides insights about ZEPOSIA's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ZEPOSIA performance, future market assessments inclusive of the ZEPOSIA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ZEPOSIA sales forecasts, along with factors driving its market.

ZEPOSIA Drug Summary

ZEPOSIA is an oral sphingosine 1-phosphate (S1P) receptor modulator developed by Bristol Myers Squibb for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as moderately to severely active ulcerative colitis (UC) in adults. The drug contains the active ingredient ozanimod, which selectively binds to S1P receptor subtypes 1 and 5, reducing lymphocyte migration into the central nervous system and inflamed gastrointestinal tissue, thereby helping control immune-mediated inflammation. Administered orally once daily following a 7-day dose titration schedule, ZEPOSIA offers a convenient non-biologic treatment option with demonstrated efficacy in reducing relapse rates in MS and inducing and maintaining remission in UC. Clinical studies such as SUNBEAM, RADIANCE, and TRUE NORTH supported its approvals by showing significant improvements in disease activity and long-term disease control, while its safety profile is generally characterized by transient bradycardia, elevated liver enzymes, infection risk, and lymphocyte count reduction requiring monitoring before and during treatment. The report provides ZEPOSIA's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ZEPOSIA Market Report

The report provides insights into:

• A comprehensive product overview including the ZEPOSIA MoA, description, dosage and administration, research and development activities in approved indications like Multiple sclerosis and Ulcerative colitis; as well as potential indication like Crohn's disease.
• Elaborated details on ZEPOSIA regulatory milestones and other development activities have been provided in ZEPOSIA market report.
• The report also highlights ZEPOSIA's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ZEPOSIA market report also covers the patents information, generic entry and impact on cost cut.
• The ZEPOSIA market report contains current and forecasted ZEPOSIA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ZEPOSIA market report also features the SWOT analysis with analyst views for ZEPOSIA in approved and potential indications.

Methodology:

The ZEPOSIA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZEPOSIA Analytical Perspective by DelveInsight

• In-depth ZEPOSIA Market Assessment

This ZEPOSIA sales market forecast report provides a detailed market assessment of ZEPOSIA for approved indication like Multiple sclerosis and Ulcerative colitis; as well as potential indication like Crohn's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ZEPOSIA sales data uptil 2034.

• ZEPOSIA Clinical Assessment

The ZEPOSIA market report provides the clinical trials information of ZEPOSIA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ZEPOSIA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ZEPOSIA Market Potential & Revenue Forecast

• Projected market size for the ZEPOSIA and its key indications
• Estimated ZEPOSIA sales potential (ZEPOSIA peak sales forecasts)
• ZEPOSIA Pricing strategies and reimbursement landscape

ZEPOSIA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ZEPOSIA Market positioning compared to existing treatments
• ZEPOSIA Strengths & weaknesses relative to competitors

ZEPOSIA Regulatory & Commercial Milestones

• ZEPOSIA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ZEPOSIA Clinical Differentiation

• ZEPOSIA Efficacy & safety advantages over existing drugs
• ZEPOSIA Unique selling points

ZEPOSIA Market Report Highlights

• In the coming years, the ZEPOSIA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ZEPOSIA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZEPOSIA's dominance.
• Other emerging products for Multiple sclerosis and Ulcerative colitis; as well as potential indication like Crohn's disease are expected to give tough market competition to ZEPOSIA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZEPOSIA in approved and potential indications.
• Analyse ZEPOSIA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ZEPOSIA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ZEPOSIA in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of ZEPOSIA? How strong is ZEPOSIA's clinical and commercial performance?
• What is ZEPOSIA's clinical trial status in each individual indications such as Multiple sclerosis and Ulcerative colitis; as well as potential indication like Crohn's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZEPOSIA Manufacturers?
• What are the key designations that have been granted to ZEPOSIA for approved and potential indications? How are they going to impact ZEPOSIA's penetration in various geographies?
• What is the current and forecasted ZEPOSIA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ZEPOSIA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ZEPOSIA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ZEPOSIA? What is the duration of therapy and what are the geographical variations in cost per patient?